Hypercalcaemia of malignancy survey
Dear colleagues,
Hypercalcaemia of malignancy is the commonest metabolic complication in cancer patients and there is a lack of evidence in this area, leading to potential variation in clinical practice.
We are interested to know how hypercalcaemia of malignancy is managed in your clinical practice. We would be grateful if you could complete and disseminate this survey.
The survey will take under 5 minutes to complete. The results will be collated and shared anonymously. Your responses are very valuable and will contribute to the ongoing work around management of hypercalcaemia in malignancy.
Thank you for your time and contribution.
BOPA, UKAOS and the Endocrinology Project Team
